Patterns of detectable viral load in a cohort of HIV-positive adolescents on antiretroviral therapy in South Africa.


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
03 2020
Historique:
received: 06 09 2019
accepted: 20 02 2020
entrez: 18 3 2020
pubmed: 18 3 2020
medline: 24 10 2020
Statut: ppublish

Résumé

Despite improved treatment and access to care, adolescent AIDS deaths are decreasing more slowly than in any other age group. There is lack of longitudinal data around adolescent adherence and the dynamics of viraemia over time. We aimed to describe patterns of detectable viral load (VL) in a cohort of adolescents attending an ARV clinic in Cape Town, South Africa. We conducted a retrospective cohort study of all patients on antiretroviral therapy aged 10 to 19 years. Participants were included if they underwent at least two VL measurements and remained in care at the Groote Schuur Hospital HIV Clinic for at least 24 months between 2002 and 2016. The primary outcome was two consecutive HIV VL >100 copies/mL, in line with the lower limit of detection of assays in use over the follow-up period. Of the 482 screened participants, 327 met inclusion criteria. Most participants had perinatally acquired HIV (n = 314; 96%), and 170 (52%) were males. Overall, there were 203 episodes of confirmed detectable VL involving 159 (49% (95% CI 43% to 54%)) participants during the follow-up period. Six participants had genotyped resistance to protease inhibitors. Four of these never suppressed, while two suppressed on salvage regimens. Total follow-up time was 1723 person years (PY), of which 880 (51%) were contributed by the 159 participants who experienced detectable VL. Overall time with detectable VL was 370 PY. This comprised 22% of total follow-up time, and 42% of the follow-up time contributed by those who experienced detectable VL. The rate of detectable VL was 11.8 (95% CI 10.3 to 13.5) episodes per 100 PY. The risk increased by 24% for each year of increasing age (Relative Risk 1.24 (95% CI 1.17 to 1.31); p < 0.0001). There was no sex difference with respect to duration (p = 0.4), prevalence (p = 0.46) and rate (p = 0.608) of detectable VL. Clinicians need to be alert to the high prevalence of detectable VL during adolescence so as to pre-empt it and act swiftly once it is diagnosed. This study helps to highlight the risk of detectable VL that is associated with increase in age as well the high proportion of time that poorly adherent adolescents spend in this state.

Identifiants

pubmed: 32180367
doi: 10.1002/jia2.25474
pmc: PMC7076279
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25474

Informations de copyright

© 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

PLoS One. 2015 Dec 14;10(12):e0144057
pubmed: 26658814
Curr Opin HIV AIDS. 2009 Nov;4(6):459-66
pubmed: 20048711
AIDS. 2014 Aug 24;28(13):1945-56
pubmed: 24845154
Trop Med Int Health. 2016 Mar;21(3):325-33
pubmed: 26681359
J Int AIDS Soc. 2017 May 16;20(Suppl 3):21528
pubmed: 28530039
AIDS Res Ther. 2017 Apr 4;14(1):20
pubmed: 28376815
AIDS Patient Care STDS. 2015 Jan;29(1):43-51
pubmed: 25372391
J Int AIDS Soc. 2013 Jun 18;16:18579
pubmed: 23782477
Cochrane Database Syst Rev. 2016 Apr 29;4:CD009794
pubmed: 27128768
Curr Opin HIV AIDS. 2018 May;13(3):236-248
pubmed: 29528851
PLoS Med. 2018 Jan 30;15(1):e1002491
pubmed: 29381702
JAMA. 2016 Jul 12;316(2):171-81
pubmed: 27404185
AIDS Behav. 2018 Mar;22(3):909-917
pubmed: 29224045
JAMA Pediatr. 2017 May 1;171(5):450-460
pubmed: 28346597
Clin Infect Dis. 2015 Jul 1;61(1):95-101
pubmed: 25838288
BMC Infect Dis. 2017 May 3;17(1):326
pubmed: 28468608
BMC Infect Dis. 2014 Nov 07;14:567
pubmed: 25373425
N Engl J Med. 2016 Sep 1;375(9):830-9
pubmed: 27424812
J Acquir Immune Defic Syndr. 2009 May 1;51(1):65-71
pubmed: 19282780
J Int AIDS Soc. 2017 May 16;20(Suppl 3):21520
pubmed: 28530036
BMC Public Health. 2014 Oct 04;14:1035
pubmed: 25280535
J Int AIDS Soc. 2020 Mar;23(3):e25474
pubmed: 32180367
Clin Infect Dis. 2017 Apr 15;64(8):1105-1112
pubmed: 28329212
Lancet Child Adolesc Health. 2018 Mar;2(3):214-222
pubmed: 30169256
AIDS. 2015 Jan 28;29(3):373-83
pubmed: 25686685
J Int AIDS Soc. 2015 Sep 16;18:20049
pubmed: 26385853
Lancet Infect Dis. 2018 Feb;18(2):188-197
pubmed: 29158101
J Acquir Immune Defic Syndr. 2014 Jul 1;66 Suppl 2:S144-53
pubmed: 24918590
Medicine (Baltimore). 2016 Jul;95(28):e3985
pubmed: 27428189

Auteurs

Rebecca Sher (R)

Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
Groote Schuur Hospital, Cape Town, South Africa.

Sipho Dlamini (S)

Groote Schuur Hospital, Cape Town, South Africa.
Division of Infectious Diseases, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Rudzani Muloiwa (R)

Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
Groote Schuur Hospital, Cape Town, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH